FDA scientists said no. HHS let the pharmacies do it anyway.
The surface story is regulatory access: six unapproved peptides, newly available through compounding pharmacies, advancing what HHS calls the MAHA agenda. The real story is in Fast Company's reporting, which found that most FDA scientific staff opposed the move before it was approved. The administration overruled its own agency's scientists. That is the sentence worth repeating.
Trump administration allows pharmacies to make popular peptides
3 sources · hover a dot to see coverage
What happened
The Department of Health and Human Services announced it will allow small compounding pharmacies to manufacture and sell six peptides that have not been approved by the Food and Drug Administration. The peptides are popular in wellness and biohacking circles and have been publicly championed by Health Secretary Robert F. Kennedy Jr. Under normal FDA rules, compounding pharmacies can only produce drugs from an approved list of substances; this decision carves out an exception for peptides currently under agency review. The move expands access to substances whose safety and efficacy have not cleared the FDA's standard approval process. Three outlets covered the announcement. What separates the coverage is whether they reported the internal FDA opposition that preceded it.
Fast Company reported the FDA dissent. The other two outlets did not.
Fast Company is the only outlet in this set that reported the internal FDA dimension: most FDA scientific staff opposed the plan before it was finalized. That is not a minor procedural footnote. It means the administration advanced a policy that its own agency's scientists had rejected. NPR and The Hill both covered the announcement as a regulatory access story, noting the peptides are unapproved and that demand may outstrip supply, but neither piece mentions the internal opposition. The Hill frames the decision as advancing the MAHA agenda. NPR notes supply may not meet demand. Neither asks how the decision got made over scientific objection.
What one side told you that the other didn't
Most FDA scientists opposed this. Two of three outlets skipped that.
Fast Company reported that most FDA scientific staff members had opposed the peptide access plan before HHS approved it. NPR and The Hill covered the same announcement without that detail. The consequence is straightforward: readers of those two outlets see a regulatory expansion; readers of Fast Company see an administration that overruled its own scientists to deliver a policy favored by the Health Secretary. Same announcement, different story.
RFK Jr.'s personal advocacy for peptides went unnamed in two outlets.
Fast Company identifies Robert F. Kennedy Jr. by name as a proponent of the peptides, framing the policy as one he personally favored. The Hill references the MAHA agenda without naming Kennedy's specific role. NPR does not attribute the push to Kennedy at all. When the Health Secretary's personal preferences are a documented factor in a regulatory outcome, leaving his name out changes how readers assess the decision's origins.
What to watch
If an FDA official or scientific staff member speaks on record about the internal opposition — in congressional testimony or a public statement — before the end of November, expect NPR and The Hill to revisit the story with the dissent framing they skipped on the initial announcement. If no one goes on record, the internal opposition finding stays isolated in Fast Company's reporting.
See how outlets across the political spectrum framed this differently — and what each side left out.